Articles by Patricia Van Arnum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Patricia Van Arnum

Advancing Flow Chemistry in API Manufacturing

Continuous flow chemistry offers potential for greater control, improved safety and environmental profiles, and efficient chemical transformations.
Apr 2, 2013

Continuous flow chemistry offers potential for greater control, improved safety and environmental profiles, and efficient chemical transformations.

Pharma Industry Outlines Opportunity for Incremental Innovation to Improve Global Health

Incremental innovation advances medicines by expanding therapeutic classes, increasing the number of available dosing options, discovering new physiological interactions of known medicines, and improving other properties of existing medicines.
Mar 6, 2013

Incremental innovation advances medicines by expanding therapeutic classes, increasing the number of available dosing options, discovering new physiological interactions of known medicines, and improving other properties of existing medicines

Fine-Chemical Producers Outline Expansion Plans at Informex

Contract API manufacturers and fine-chemical producers proceed with select investment in capacity and service additions.
Mar 6, 2013

Contract API manufacturers and fine-chemical producers proceed with select investment in capacity and service additions.

The Weaknesses and Strengths of the Global API Market

Supply-demand fundamentals show strong growth for generic APIs as gains in innovator APIs lag.
Mar 6, 2013

Supply-demand fundamentals show strong growth for generic APIs as gains in innovator APIs lag.

Advancing analytical testing and instrumentation for biopharmaceuticals

Instrument manufacturers and testing service providers are offering improved tools to biologic charaterization.
Mar 2, 2013

Instrument manufacturers and testing service providers are offering improved tools to biologic charaterization.

Advances in PAT for Parenteral Drug Manufacturing

Applying quality-by-design and process analytical technology facilitates process understanding and control of various operations in lyophilization.
Mar 2, 2013

Applying quality-by-design and process analytical technology facilitates process understanding and control of various operations in lyophilization.

Navigating the Global Manufacturing Supply Chain

As the strategic value of emerging markets increase, pharmaceutical companies increase their R&D and manufacturing investments.
Mar 2, 2013

As the strategic value of emerging markets increase, pharmaceutical companies increase their R&D and manufacturing investments.

Quality by Design in Excipients

Factors for assessing excipient variability, the associated challenges developers need to address to design and manufacture solid oral drug products, and solutions for such challenges are examined.
Mar 1, 2013

Factors for assessing excipient variability, the associated challenges developers need to address to design and manufacture solid oral drug products, and solutions for such challenges are examined.

Pharma Companies Increase R&D for Neglected Tropical Disease

Pharma companies intensify R&D efforts to address treatments for neglected tropical diseases in the developing world.
Feb 6, 2013

Pharma companies intensify R&D efforts to address treatments for neglected tropical diseases in the developing world.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here